TapewireFind a company

person · Reporting owner

KIM AUSTIN D.

Disclosed activity across 1 company

Tapewire entity
95346
SEC CIK
0001746240

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ACADIA PHARMACEUTICALS INCACAD · Entity 3913EVP,General Counsel, SecretaryJanuary 06, 2024January 09, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date January 06, 2024 · Filed January 09, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect46,901 Ending reported balance After 2024-01-08 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-01-06 · Exercise / conversion · Acquired 1,634 · Balance 47,491

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Row 2 · 2024-01-08 · Sale · Disposed 590 · Balance 46,901

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-01-06 · Exercise / conversion · Disposed 1,634 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 08, 2024 Filed Jan 9, 2024 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 590 $29.96 $17,676.40
Disclosure

SEC source: 0001209191-24-001267 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,901

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
January 06, 2024 Filed Jan 9, 2024 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,634 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001267 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,634 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Read SEC document
January 06, 2024 Filed Jan 9, 2024 23:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,634 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-001267 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
October 06, 2023 Filed Oct 7, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 16,369 $21.96 $359,463.24
Disclosure

SEC source: 0001209191-23-052390 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,857

F3 · price: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
October 05, 2023 Filed Oct 7, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 36,174 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-052390 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,289

Underlying: Common Stock · 36,174 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
October 05, 2023 Filed Oct 7, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 36,174 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-052390 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F2 · balance_after: Includes 539 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023.

Read SEC document
May 01, 2023 Filed May 2, 2023 23:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 917 $21.18 $19,422.06
Disclosure

SEC source: 0001209191-23-026746 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,513

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:14 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 18,172 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-027204 · doc4.xml · derivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,172

Underlying: Common Stock · 18,172 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:14 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 59,957 $0.00 Strike: $21.75 $0.00
Disclosure

SEC source: 0001209191-23-027204 · doc4.xml · derivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,957

Underlying: Common Stock · 59,957 shares

Expires 2033-05-01

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
April 29, 2023 Filed May 2, 2023 23:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,005 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026746 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,005 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

Read SEC document
April 29, 2023 Filed May 2, 2023 23:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,005 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-026746 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,430

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

Read SEC document
April 06, 2023 Filed Apr 8, 2023 00:32 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,456 $18.16 $26,440.96
Disclosure

SEC source: 0001209191-23-023861 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,425

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:32 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 4,773 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-023861 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,319

Underlying: Common Stock · 4,773 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2023 Filed Apr 8, 2023 00:32 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 4,773 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-023861 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 803 $18.78 $15,080.34
Disclosure

SEC source: 0001209191-23-013469 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,108

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,214 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-013469 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,428

Underlying: Common Stock · 2,214 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Read SEC document
February 23, 2023 Filed Feb 28, 2023 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,214 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-013469 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
January 09, 2023 Filed Jan 11, 2023 01:20 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 589 $17.13 $10,089.75
Disclosure

SEC source: 0001209191-23-002894 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,697

F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
January 06, 2023 Filed Jan 11, 2023 01:20 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,633 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-002894 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,634

Underlying: Common Stock · 1,633 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Read SEC document
January 06, 2023 Filed Jan 11, 2023 01:20 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,633 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-002894 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F2 · balance_after: Includes 911 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program.

Read SEC document
May 02, 2022 Filed May 4, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 894 $18.18 $16,254.71
Disclosure

SEC source: 0001209191-22-026938 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,742

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.425, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
April 29, 2022 Filed May 4, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,005 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-026938 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,005

Underlying: Common Stock · 3,005 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020.

Read SEC document
April 29, 2022 Filed May 4, 2022 00:51 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,005 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-026938 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 22:47 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 96,463 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,463

Underlying: Common Stock · 96,463 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 22:47 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 19,092 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,092

Underlying: Common Stock · 19,092 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023.

Read SEC document
April 05, 2022 Filed Apr 7, 2022 22:47 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 65,517 $0.00 Strike: $25.75 $0.00
Disclosure

SEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,517

Underlying: Common Stock · 65,517 shares

Expires 2032-04-05

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:42 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 2,213 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013277 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,642

Underlying: Common Stock · 2,213 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:42 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 782 $23.80 $18,611.60
Disclosure

SEC source: 0001209191-22-013277 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,631

F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 22:42 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 2,213 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-013277 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,413

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 06, 2022 Filed Jan 10, 2022 23:24 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,633 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-002750 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,267

Underlying: Common Stock · 1,633 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Read SEC document
January 06, 2022 Filed Jan 10, 2022 23:24 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 574 $23.05 $13,230.70
Disclosure

SEC source: 0001209191-22-002750 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,200

F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
January 06, 2022 Filed Jan 10, 2022 23:24 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,633 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-002750 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,774

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 365 shares of the Issuer's common stock acquired by the reporting person on May 15, 2021 and 405 shares acquired by the reporting person on November 15, 2021, pursuant to an employee stock purchase program.

Read SEC document
April 30, 2021 Filed Apr 30, 2021 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,054 $20.33 $21,427.82
Disclosure

SEC source: 0001209191-21-029358 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,371

F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
April 29, 2021 Filed Apr 30, 2021 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,005 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-029358 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,010

Underlying: Common Stock · 3,005 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

Read SEC document
April 29, 2021 Filed Apr 30, 2021 22:54 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,005 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-029358 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F2 · balance_after: The amount of securities beneficially owned reported in Column 5 above has been adjusted to correct an error in the Reporting Person's prior Form 4 caused by the failure to carry over the correct number of shares from the prior report. The number of shares owned prior to the transactions reported herein was 9,420 shares.

Read SEC document
February 23, 2021 Filed Feb 26, 2021 02:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 8,855 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-014558 · doc4.xml · derivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,855

Underlying: Common Stock · 8,855 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022.

Read SEC document
February 23, 2021 Filed Feb 26, 2021 02:46 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 32,608 $0.00 Strike: $49.74 $0.00
Disclosure

SEC source: 0001209191-21-014558 · doc4.xml · derivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,608

Underlying: Common Stock · 32,608 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document
February 04, 2021 Filed Feb 9, 2021 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 2,107 $50.61 $106,635.27
Disclosure

SEC source: 0001209191-21-008658 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,911

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
February 04, 2021 Filed Feb 9, 2021 02:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantCommon Stock 6,009 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-008658 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,018

F1 · kind: On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above.

Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:30 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 1,633 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-002834 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,900

Underlying: Common Stock · 1,633 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:30 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 678 $53.34 $36,164.52
Disclosure

SEC source: 0001209191-21-002834 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,518

F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:30 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 1,633 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-002834 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,196

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 712 shares of the Issuer's common stock acquired by the reporting person on November 13, 2020 pursuant to an employee stock purchase program.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 20:12 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionStock Option (Right to Buy) · Derivative 8,750 $0.00 Strike: $17.58 $0.00
Disclosure

SEC source: 0001209191-20-056219 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,750

Underlying: Common Stock · 8,750 shares

Expires 2028-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on July 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 20:12 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 8,750 $45.10 $394,636.38
Disclosure

SEC source: 0001209191-20-056219 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,851

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 9/18/2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.525, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 20:12 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 8,750 $17.58 $153,825.00
Disclosure

SEC source: 0001209191-20-056219 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,410 shares of the Issuer's common stock acquired by the reporting person on May 15, 2020 pursuant to an employee stock purchase program.

Read SEC document
April 30, 2020 Filed May 1, 2020 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 SaleCommon Stock 1,072 $49.22 $52,763.84
Disclosure

SEC source: 0001209191-20-026619 · doc4.xml · nonDerivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,441

F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

Read SEC document
April 29, 2020 Filed May 1, 2020 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionRestricted Stock Units · Derivative 3,004 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-026619 · doc4.xml · derivative · entry 3

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,015

Underlying: Common Stock · 3,004 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020.

Read SEC document
April 29, 2020 Filed May 1, 2020 22:00 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 Exercise / conversionCommon Stock 3,004 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-026619 · doc4.xml · nonDerivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

Read SEC document
January 06, 2020 Filed Jan 8, 2020 23:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantRestricted Stock Units · Derivative 6,533 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-002600 · doc4.xml · derivative · entry 2

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,533

Underlying: Common Stock · 6,533 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Read SEC document
January 06, 2020 Filed Jan 8, 2020 23:06 UTC ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 GrantStock Options (Right to Buy) · Derivative 23,709 $0.00 Strike: $42.81 $0.00
Disclosure

SEC source: 0001209191-20-002600 · doc4.xml · derivative · entry 1

KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,709

Underlying: Common Stock · 23,709 shares

Expires 2030-01-06

F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.